China NMPA Conditionally Approves Iparomlimab and Tuvonralimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #Iparomlimab #Tuvonralimab #Qibeian #CervicalCancer #Immunotherapy #BispecificAntibody #QiluPharmaceutical #ChineseInnovativeDrugs #Oncology